Medical/Pharmaceuticals
Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH
Results published by the DETECT study group indicate the relevance of assessing biomarker expression in Circulating Tumor Cells (CTCs) with the minimally invasive liquid biopsy-based CELLSEARCH® platform to optimize treatment strategy and outcome in patients at an advanced stage of their disease....
2024-01-09 18:55
1289
TOKIWA PHYTOCHEMICAL CO., LTD. Announces Latest Clinical Study of VENETRON (R) on Menstrual Well-being
SAKURA, Japan, Jan. 9, 2024 /PRNewswire/ -- TOKIWA PHYTOCHEMICAL CO., LTD. (hereinafter "Tokiwa"),Japan, has announced the publication of the latest research on VENETRON (R), extracted from rafuma leaves. The study, titled "Effect of Apocynum venetum Leaf Extract (VENETRON (R)) on Unidentified C...
2024-01-09 15:00
1483
Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock code ：688176.SH) has announced its set-up of the Women's Health Business Unit for commercialization. This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women'...
2024-01-09 12:25
1656
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib（ABSK021） has been granted orphan drug designation（ODD） by the European Medicines Agency (EMA) for the treatm...
2024-01-09 08:30
1498
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
ROCKVILLE, Md. and SUZHOU, China, Jan. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...
2024-01-09 08:00
4043
GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform
South Korea's first CAR-NK cell therapy cleared for human trials in Australia
and domestically; Cancer Moonshot participant GC Cell partnering with medical
AI leader Lunit to collaborate on AB-201 clinical development
YONGIN, South Korea and SYDNEY, Jan. 9, 2024 /PRNewswire/ -- GC Cell
2024-01-09 00:00
1891
Novaestiq Unveils Platform of Innovations; Poised to Disrupt the US Aesthetic Market
SOUTHLAKE, Texas, Jan. 8, 2024 /PRNewswire/ -- Novaestiq Corp., a growth-oriented aesthetic and medical dermatological innovations company, focused on delivering a platform of creative solutions to practices and patients, proudly announces its definitive agreement with Croma-Pharma GmbH to be th...
2024-01-08 22:28
1417
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, b...
2024-01-08 22:00
5152
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap
HONG KONG, Jan. 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced thatMichelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the Company's achievements in the development of new bispecific a...
2024-01-08 21:38
1475
YS Biopharma Announces Changes to its Board Committees
GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2024-01-08 21:00
1558
Novel Technology Transforms Baldness Treatment Using Beard and Body Hair
LOS ANGELES, Jan. 8, 2024 /PRNewswire/ -- The ongoing puzzle of having lots of body hair but little on the scalp has confounded many dealing with hair loss. A breakthrough emerges with Dr. U Hair and Skin Clinic reports a pioneering study published in the esteemed Dermatologic Surgery journal tit...
2024-01-08 21:00
1669
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
* Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in m...
2024-01-08 20:30
1568
The World's First Clinical Base Editing Therapy for Hemoglobinopathy
CorrectSequence Therapeutics' CS-101 Successfully Cures One Patient of
Transfusion-Dependent β-Thalassemia
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 8, 2024, Shanghai,China,
CorrectSequence Therapeutics Co., Ltd.
2024-01-08 19:46
2022
Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024 NEWARK, Del. and NANJING, China, Jan. 8, 2024 /PRNewswire/ -- The Partner ...
2024-01-08 19:35
1224
So-Young Announces Update on Repurchase and Cancellation of Shares
BEIJING, Jan. 8, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that during the term of the Co...
2024-01-08 19:00
4614
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
* The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S. * The site is expected to employ 250 people when fully operational. WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Resea...
2024-01-08 17:52
4474
Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report
Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organ...
2024-01-08 16:00
1549
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biops...
2024-01-08 15:30
1580
Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum's Disease
NEW TAIPEI CITY, Jan. 8, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the United States Food and Drug Administration (U.S. FDA) has accepted the CBL-514 Investigational New Drug (IND) application of CBL-0202 DD Phase 2 Study to treat Dercum's Disease. Dercum's disease...
2024-01-08 13:25
2243
2024 Trend Forecast for Cosmetic Surgery & Medical Aesthetics in Singapore
As the demand for medical aesthetics and cosmetic surgery continues to grow, Dr Ivan Puah, a liposuction and aesthetic doctor from Amaris B. Clinic, identifies a distinct shift in consumer needs inSingapore. SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Dr Ivan Puah, Medical Director of Amaris B. Cli...
2024-01-08 09:00
420
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 300 media titles]
2025-01-23 09:00
Infobip Research Unveils Opportunities for Brands to Engage Customers with Rich Communication Services (RCS) across APAC
[Picked up by 291 media titles]
2025-01-20 21:09
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
7062
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4924
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
4899